Disease burden of herpes zoster in Korea
- PMID: 20181512
- DOI: 10.1016/j.jcv.2010.01.003
Disease burden of herpes zoster in Korea
Abstract
Background: The occurrence of herpes zoster can deteriorate the quality of life considerably, resulting in high disease burden. While Korea is assumed to have high disease burden of herpes zoster, there has been no researches analyzing this.
Objectives: We performed this study to investigate the disease burden of herpes zoster in the Korean population as a whole.
Study design: We used the database of the Health Insurance Review & Assessment Service of Korea and analyzed the data of patients who had herpes zoster as a principal diagnosis during the period from 2003 to 2007. We investigated the annual prevalence, rate of clinical visits, rate of hospitalization, and the pattern of medical services use. The socioeconomic burden of herpes zoster was calculated by a conversion into cost.
Results: Rates of clinic visits and hospitalizations due to herpes zoster during the 5-year period from 2003 to 2007 were 7.93-12.54 per 1000 population and 0.22-0.32 per 1000 population, respectively. Prevalence rates according to age increased sharply after 50 years and reached a peak at 70 years. The total socioeconomic cost of herpes zoster was $75.9-143.8 million per year, increasing every year by 14-20%.
Conclusions: There is a heavy socioeconomic burden due to herpes zoster in Korea and indicate that appropriate policies need to be established to reduce this burden. Additional researches are also necessary to assess the safety, efficacy and cost-effectiveness of a herpes zoster vaccine in the Korean population.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan.Vaccine. 2010 Feb 3;28(5):1217-20. doi: 10.1016/j.vaccine.2009.11.029. Epub 2009 Nov 26. Vaccine. 2010. PMID: 19944790
-
The burden and cost of hospitalised varicella and zoster in Australian children.Vaccine. 2004 Dec 21;23(6):755-61. doi: 10.1016/j.vaccine.2004.07.025. Vaccine. 2004. PMID: 15542199
-
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17. Vaccine. 2007. PMID: 17980938
-
The burden of herpes zoster and postherpetic neuralgia in the United States.J Am Osteopath Assoc. 2007 Mar;107(3 Suppl 1):S2-7. J Am Osteopath Assoc. 2007. PMID: 17488884 Review.
-
Vaccination: a new option to reduce the burden of herpes zoster.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Expert Rev Vaccines. 2010. PMID: 20192716 Review.
Cited by
-
Herpes zoster infection in patients with inflammatory bowel disease.Korean J Intern Med. 2025 May;40(3):347-356. doi: 10.3904/kjim.2024.342. Epub 2025 Apr 30. Korean J Intern Med. 2025. PMID: 40360218 Free PMC article. Review.
-
Awareness, Knowledge, and Vaccine Acceptability of Herpes Zoster in Korea: A Multicenter Survey of 607 Patients.Ann Dermatol. 2015 Oct;27(5):531-8. doi: 10.5021/ad.2015.27.5.531. Epub 2015 Oct 2. Ann Dermatol. 2015. PMID: 26512167 Free PMC article.
-
A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.Hum Vaccin Immunother. 2024 Dec 31;20(1):2344983. doi: 10.1080/21645515.2024.2344983. Epub 2024 May 20. Hum Vaccin Immunother. 2024. PMID: 38767209 Free PMC article.
-
Risk Factor and Prevention of Postherpetic Neuralgia.Korean J Pain. 2015 Jul;28(3):167-8. doi: 10.3344/kjp.2015.28.3.167. Epub 2015 Jul 1. Korean J Pain. 2015. PMID: 26175875 Free PMC article. No abstract available.
-
Disease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective Survey.PLoS One. 2016 Apr 7;11(4):e0152660. doi: 10.1371/journal.pone.0152660. eCollection 2016. PLoS One. 2016. PMID: 27055179 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical